Foresite Capital Management III’s Cymabay Therapeutics CBAY Stock Holding History

Foresite Capital Management III’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$5.75M	Hold	1,641,804	–	–	15.17%	4
2022 Q2	$4.84M	Hold	1,641,804	–	–	17.57%	3
2022 Q1	$5.11M	Hold	1,641,804	–	–	15.56%	4
2021 Q4	$5.55M	Hold	1,641,804	–	–	14.05%	4
2021 Q3	$5.99M	Hold	1,641,804	–	–	8.31%	4
2021 Q2	$7.16M	Hold	1,641,804	–	–	7.59%	7
2021 Q1	$7.45M	Hold	1,641,804	–	–	6.55%	7
2020 Q4	$9.42M	Hold	1,641,804	–	–	10.95%	7
2020 Q3	$11.9M	Buy	1,641,804 +41,846	+3%	+$224K	8.85%	6
2020 Q2	$5.58M	Buy	+1,599,958	New	+$4.62M	4.97%	6
2020 Q1	–	Sell	-1,504,710	Closed	-$2.95M	–	12
2019 Q4	$2.95M	Sell	1,504,710 -3,381	-0.2%	-$12.7K	1.65%	9
2019 Q3	$7.72M	Sell	1,508,091 -79,010	-5%	-$478K	2.95%	13
2019 Q2	$11.4M	Hold	1,587,101	–	–	3.73%	11
2019 Q1	$21.1M	Hold	1,587,101	–	–	5.49%	6
2018 Q4	$12.5M	Buy	1,587,101 +25,061	+2%	+$239K	4.1%	9
2018 Q3	$17.3M	Hold	1,562,040	–	–	3.82%	7
2018 Q2	$21M	Hold	1,562,040	–	–	4.51%	7
2018 Q1	$20.3M	Buy	1,562,040 +962,040	+160%	+$12M	4.42%	8
2017 Q4	$5.52M	Hold	600,000	–	–	1.55%	13
2017 Q3	$4.84M	Buy	+600,000	New	+$4.06M	1.33%	15

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Foresite Capital Management III's CBAY Position: Q3 2022 in Review

Foresite Capital Management III held its Cymabay Therapeutics (CBAY) position steady in Q3 2022 at 1,641,804 shares worth $5.75M. The position accounts for 15.17% of the portfolio, ranked #4.

Foresite Capital Management III first reported a position in CBAY in Q3 2017 and has held it in 20 quarters since. The position peaked at $21.1M in Q1 2019. 100 funds tracked by Wall St. Rank hold CBAY as of Q3 2022.

Foresite Capital Management III held 1,641,804 shares of Cymabay Therapeutics worth $5.75M as of Q3 2022.
Foresite Capital Management III left its Cymabay Therapeutics share count unchanged in Q3 2022.
Cymabay Therapeutics made up 15.17% of Foresite Capital Management III's portfolio in Q3 2022, its #4 holding.
Foresite Capital Management III first reported a position in Cymabay Therapeutics in Q3 2017 and has held it in 20 quarters since.
Foresite Capital Management III's Cymabay Therapeutics position peaked at $21.1M in Q1 2019.
100 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2022.

Based on Foresite Capital Management III's 13F filing for Q3 2022, filed 14 Nov 2022.